Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.

@article{Comstock2010SafetyAT,
  title={Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.},
  author={Timothy L. Comstock and Michael R Paterno and Heleen H Decory and Dale W Usner},
  journal={Clinical drug investigation},
  year={2010},
  volume={30 10},
  pages={675-85}
}
BACKGROUND Besifloxacin is a novel fluoroquinolone, specifically a chloro-fluoroquinolone, with potent broad-spectrum bactericidal activity for the topical treatment of bacterial conjunctivitis. OBJECTIVE The objective of this report was to provide a comprehensive assessment of the safety and tolerability of besifloxacin ophthalmic suspension 0.6% across clinical and phase I safety studies. METHODS Data were drawn from two phase I safety studies in healthy adults, an open-label, phase II… CONTINUE READING